MA31022B1 - Derives de l'isoquinoleine et de l'isoquinoleinone substituees - Google Patents

Derives de l'isoquinoleine et de l'isoquinoleinone substituees

Info

Publication number
MA31022B1
MA31022B1 MA32037A MA32037A MA31022B1 MA 31022 B1 MA31022 B1 MA 31022B1 MA 32037 A MA32037 A MA 32037A MA 32037 A MA32037 A MA 32037A MA 31022 B1 MA31022 B1 MA 31022B1
Authority
MA
Morocco
Prior art keywords
isoquinoleinone
derivatives
substituted isoquinoline
rho
kinase
Prior art date
Application number
MA32037A
Other languages
English (en)
Inventor
Oliver Plettenburg
Armin Hofmeister
Jochen Goerlitzer
Matthias Loehn
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA31022B1 publication Critical patent/MA31022B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)

Abstract

L'INVENTION CONCERNE DES DÉRIVÉS D'ISOQUINOLINE ET D'ISOQUINOLONE 6-SUBSTITUÉS REPRÉSENTÉS PAR LA FORMULE (I), UTILISÉS DANS LE TRAITEMENT ET/OU LA PRÉVENTION DE MALADIES ASSOCIÉES À LA RHO-KINASE ET/OU À LA PHOSPHORYLATION MÉDIÉE PAR LA RHO-KINASE DE LA PHOSPHATASE DE LA CHAÎNE LÉGÈRE DE LA MYOSINE, ET DES COMPOSITIONS CONTENANT LESDITS COMPOSÉS.
MA32037A 2006-12-27 2009-06-24 Derives de l'isoquinoleine et de l'isoquinoleinone substituees MA31022B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06026896 2006-12-27

Publications (1)

Publication Number Publication Date
MA31022B1 true MA31022B1 (fr) 2009-12-01

Family

ID=38001966

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32037A MA31022B1 (fr) 2006-12-27 2009-06-24 Derives de l'isoquinoleine et de l'isoquinoleinone substituees

Country Status (22)

Country Link
US (1) US8748614B2 (fr)
EP (1) EP2114920A1 (fr)
JP (1) JP5405315B2 (fr)
KR (1) KR20090094338A (fr)
CN (1) CN101573353B (fr)
AU (1) AU2007338408B2 (fr)
BR (1) BRPI0720986A2 (fr)
CA (1) CA2673918C (fr)
CO (1) CO6210826A2 (fr)
CR (1) CR10814A (fr)
DO (1) DOP2009000162A (fr)
EC (1) ECSP099470A (fr)
IL (1) IL199537A (fr)
MA (1) MA31022B1 (fr)
MX (1) MX2009006517A (fr)
MY (1) MY155279A (fr)
NO (1) NO20092424L (fr)
RU (1) RU2009128693A (fr)
SV (1) SV2009003312A (fr)
TN (1) TN2009000268A1 (fr)
WO (1) WO2008077552A1 (fr)
ZA (1) ZA200903552B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2580108T3 (es) 2005-07-11 2016-08-19 Aerie Pharmaceuticals, Inc Compuestos de isoquinolina
ES2729424T3 (es) 2006-09-20 2019-11-04 Aerie Pharmaceuticals Inc Inhibidores de Rho cinasa
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8455514B2 (en) 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
JP5715561B2 (ja) * 2008-06-24 2015-05-07 サノフイ 二及び多環式置換イソキノリン及びイソキノリノン誘導体
JP5713893B2 (ja) * 2008-06-24 2015-05-07 サノフイ Ｒｈｏ−キナーゼ阻害剤としての置換イソキノリン類及びイソキノリノン類
JP5714485B2 (ja) * 2008-06-24 2015-05-07 サノフイ ６−置換イソキノリン類及びイソキノリノン類
EP2317849A4 (fr) * 2008-06-26 2011-11-02 Inspire Pharmaceuticals Inc Procédé permettant de traiter des maladies pulmonaires par des composés inhibiteurs de rho kinase
US8410147B2 (en) 2008-06-26 2013-04-02 Inspire Pharmaceuticals, Inc. Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds
US8450344B2 (en) * 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
EP3828172A1 (fr) 2009-05-01 2021-06-02 Aerie Pharmaceuticals, Inc. Inhibiteurs à double mecanisme pour le traitement d'une maladie
US20140275160A1 (en) 2013-03-15 2014-09-18 Aerie Pharmaceuticals, Inc. Combination therapy
CN105829287B (zh) 2013-12-20 2019-08-27 埃斯蒂文制药股份有限公司 具有抗疼痛的多重模式活性的哌嗪衍生物
FR3017868A1 (fr) 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN105085478B (zh) * 2014-04-28 2019-04-12 南京明德新药研发股份有限公司 异喹啉磺胺衍生物及其药物组合物和制药用途
CA2957898C (fr) 2014-09-15 2023-02-21 Rugen Holdings (Cayman) Limited Derives de pyrrolopyrimidine a titre d'antagonistes des recepteurs nmda nr2b
US10221182B2 (en) 2015-02-04 2019-03-05 Rugen Holdings (Cayman) Limited 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists
US10584127B2 (en) 2015-06-01 2020-03-10 Rugen Holdings (Cayman) Limited 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists
CN105237474B (zh) * 2015-09-30 2017-08-29 沈阳药科大学 6‑羟基‑7‑芳甲酰基喹啉酮类化合物的制备及其应用
JP6832946B2 (ja) 2015-11-17 2021-02-24 アエリエ ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤およびその中間体の調製方法
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
CN109640966A (zh) 2016-08-31 2019-04-16 爱瑞制药公司 眼用组合物
WO2018098128A1 (fr) 2016-11-22 2018-05-31 Rugen Holdings (Cayman) Limited Traitement de troubles du spectre autistique, de troubles obsessivo-compulsifs et de troubles de l'anxiété
WO2018183911A1 (fr) 2017-03-31 2018-10-04 Aerie Pharmaceuticals, Inc. Composés d'amide aryl cyclopropyl-amino-isoquinolinyl
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
CN109180586B (zh) * 2018-10-10 2022-03-08 成都理工大学 作为Rho激酶抑制剂的六氢氮杂卓-4-基氧基苯甲酰胺类化合物
WO2020092528A1 (fr) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Composés 6-azabenzimidazole substitués ayant une activité inhibitrice de hpk1
PE20211655A1 (es) 2018-10-31 2021-08-24 Gilead Sciences Inc Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2485537B2 (fr) * 1977-04-13 1986-05-16 Anvar Dipyrido(4,3-b)(3,4-f)indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
WO1992002476A1 (fr) 1990-07-31 1992-02-20 E.I. Du Pont De Nemours And Company Equilibrage catalytique d'halocarbones selectionnes
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
NZ334613A (en) 1996-08-12 2002-02-01 Welfide Corp Pharmaceutical agents comprising Rho kinase inhibitor
JPH1087629A (ja) 1996-09-18 1998-04-07 Fujisawa Pharmaceut Co Ltd 新規イソキノリン誘導体、およびその医薬用途
US6362191B1 (en) 1997-08-29 2002-03-26 Zeneca Ltd. Aminometyl oxooxazolidinyl benzene derivatives
TW575567B (en) * 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
GB9912701D0 (en) 1999-06-01 1999-08-04 Smithkline Beecham Plc Novel compounds
US6541456B1 (en) 1999-12-01 2003-04-01 Isis Pharmaceuticals, Inc. Antimicrobial 2-deoxystreptamine compounds
CA2398388A1 (fr) 2000-01-20 2001-07-26 Koji Kato Nouveaux composes de piperidine et medicaments contenant ces composes
US7217722B2 (en) * 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
WO2001064238A2 (fr) 2000-02-29 2001-09-07 Curis, Inc. Procédés et compositions permettant de réguler les adipocytes
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0013060D0 (en) 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
WO2002034712A1 (fr) 2000-10-27 2002-05-02 Takeda Chemical Industries, Ltd. Procede de preparation de composes aromatiques substitues et produits intermediaires associes
JP2004520347A (ja) 2001-01-15 2004-07-08 グラクソ　グループ　リミテッド Ｌｄｌ−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体
SE0101038D0 (sv) 2001-03-23 2001-03-23 Astrazeneca Ab Novel compounds
AU2002256418A1 (en) 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Inhibitors of bace
US7199147B2 (en) * 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
WO2003024450A1 (fr) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methodes de traitement des maladies a prions
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
JPWO2004009555A1 (ja) * 2002-07-22 2005-11-17 旭化成ファーマ株式会社 ５−置換イソキノリン誘導体
EP1550660A1 (fr) 2002-09-12 2005-07-06 Kirin Beer Kabushiki Kaisha Derives d'isoquinoline d'inhibition des kinases et medicaments contenant ceux-ci
US20050014783A1 (en) 2003-05-29 2005-01-20 Schering Aktiengesellschaft Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
EP1638939A2 (fr) 2003-06-24 2006-03-29 Neurosearch A/S Derives de noyaux aza et utilisation de ceux-ci comme inhibiteurs de la recapture des neurotransmetteurs monoaminergiques
US7691879B2 (en) 2003-09-23 2010-04-06 Merck Sharp & Dohme Corp. Isoquinoline potassium channel inhibitors
JP4718467B2 (ja) 2003-09-23 2011-07-06 メルク・シャープ・エンド・ドーム・コーポレイション イソキノリノンカリウムチャネル阻害剤
US20050067037A1 (en) 2003-09-30 2005-03-31 Conocophillips Company Collapse resistant composite riser
EP1671962A1 (fr) 2003-10-10 2006-06-21 Ono Pharmaceutical Co., Ltd. Nouveau compose heterocyclique fondu et utilisation correspondante
WO2005054202A1 (fr) 2003-11-25 2005-06-16 Eli Lilly And Company Derives de 7-phenyl-isoquinoline-5-sulfonylamino en tant qu'inhibiteurs de akt (proteine kinase b)
JP2005232175A (ja) * 2004-01-21 2005-09-02 Asahi Kasei Pharma Kk ５−置換イソキノリン医薬
WO2005074535A2 (fr) 2004-01-30 2005-08-18 Eisai Co., Ltd. Inhibiteurs de cholinesterase pour des troubles de la colonne vertebrale
WO2005087226A1 (fr) 2004-03-05 2005-09-22 Eisai Co., Ltd. Traitement de cadasil avec des inhibiteurs de la cholinesterase
SE0400850D0 (sv) 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
US7517991B2 (en) * 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
SI1912949T1 (sl) 2005-07-26 2011-12-30 Sanofi Sa Cikloheksilamin izokinolonski derivati kot inhibitorji Rho-kinaze
PT1910333E (pt) 2005-07-26 2013-08-01 Sanofi Sa Derivados de isoquinolona substituída com piperidinilo como inibidores da rho-cinase
TW200745101A (en) 2005-09-30 2007-12-16 Organon Nv 9-Azabicyclo[3.3.1]nonane derivatives
TW200738682A (en) * 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
US7618985B2 (en) * 2005-12-08 2009-11-17 N.V. Organon Isoquinoline derivatives
US7511063B2 (en) * 2006-08-16 2009-03-31 Schering Corporation High affinity quinoline-based kinase ligands
US7893088B2 (en) 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives
PT2102164E (pt) 2006-12-27 2011-01-21 Sanofi Aventis Derivados de isoquinolina e de isoquinolinona substituída com cicloalquilamina
JP5313919B2 (ja) 2006-12-27 2013-10-09 サノフイ 新規な置換イソキノリン及びイソキノリノン誘導体

Also Published As

Publication number Publication date
IL199537A (en) 2013-11-28
CN101573353A (zh) 2009-11-04
MY155279A (en) 2015-09-30
US8748614B2 (en) 2014-06-10
AU2007338408B2 (en) 2012-07-26
EP2114920A1 (fr) 2009-11-11
IL199537A0 (en) 2010-03-28
DOP2009000162A (es) 2009-07-31
CA2673918C (fr) 2015-02-17
US20100105650A1 (en) 2010-04-29
CR10814A (es) 2009-08-12
CA2673918A1 (fr) 2008-07-03
TN2009000268A1 (en) 2010-10-18
CN101573353B (zh) 2014-08-06
BRPI0720986A2 (pt) 2014-03-11
AU2007338408A1 (en) 2008-07-03
ZA200903552B (en) 2010-04-28
MX2009006517A (es) 2009-06-26
JP5405315B2 (ja) 2014-02-05
RU2009128693A (ru) 2011-02-10
JP2010514717A (ja) 2010-05-06
ECSP099470A (es) 2009-07-31
NO20092424L (no) 2009-09-18
CO6210826A2 (es) 2010-10-20
WO2008077552A1 (fr) 2008-07-03
KR20090094338A (ko) 2009-09-04
SV2009003312A (es) 2010-02-05

Similar Documents

Publication Publication Date Title
MA31024B1 (fr) Nouveaux derives de l'isoquinoleine et de l'isoquinoleinone substituees
MA31021B1 (fr) Derives de l'isoquinoleine et de l'isoquinoleinone substituees en tant qu'inhibiteurs de la rho-kinase
MA31076B1 (fr) Dérivés de l'isoquinoléine et de l'isoquinoléinone substitués par une cycloalkylamine.
MA31075B1 (fr) Dérivés d'isoquinolone substitués par une cycloalkylamine.
MA29535B1 (fr) Derives d'isoquinoline utilises en tant qu'inhibiteurs de rhokinase
MA29636B1 (fr) Dérivés de l'isoquinolone substitués par pipéridinyle en tant qu'inhibiteur de la Rho-kinase
MA29639B1 (fr) Derives de cyclohexylamine isoquinolone en tant qu'inhibiteurs de la rhokinase.
MA31023B1 (fr) Derives de l'isoquinolone et de l'isoquinoleinone substituees par une cycloalkylamine
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
ATE554072T1 (de) Cycloalkylaminsubstituierte isochinolinderivate
MY155279A (en) Substituted isoquinoline and isoquinolinone derivatives
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
TNSN07022A1 (fr) Derives de pyridine
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MA32399B1 (fr) Isoquinoléines et isoquinoléinones 6-substituées.
MA32401B1 (fr) Derives d'isoquinoleine et d'isoquinoleinone substitues bi-et polycycliques